InMed Pharmaceuticals Inc. (INM) Form 10-K — Sep 9, 2026
InMed Pharmaceuticals' fiscal 2026 10-K discloses that operating losses have raised substantial doubt about the company's ability to continue as a going concern. The company wound down BayMedica, its only revenue-generating business segment, incurring roughly $555,000 in severance and related costs with about $120,000 more expected through year-end. The filing makes clear the pending merger with Mentari — agreed May 19, 2026 and amended July 6, 2026 — is now existential for InMed. If the deal is not consummated, the board may pursue dissolution and liquidation, and holders of the company's roughly 5.5 million shares could lose all or a significant portion of their investment.
Key figures
- Shares Outstanding
- 5493735
- Nasdaq minimum bid price usd
- 1
- Full time employees sep1 2026
- 6
- Nasdaq new mvls requirement usd
- 5000000
- Phase2 eb trial patients enrolled
- 19
- Severance costs baymedica winddown usd
- 555000
- Non affiliate market value dec31 2025 usd
- 2967434
- Additional winddown expenditures expected usd
- 120000
Price after filing
Close on the filing date to close N calendar days later (from $1.31). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.